Citius Oncology, Inc. (CTOR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Citius Oncology, Inc. (CTOR) Healthcare & Pipeline Overview

Citius Oncology, Inc., a subsidiary of Citius Pharmaceuticals, focuses on developing targeted oncology therapies, notably LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma. Operating within the drug manufacturing sector, the company addresses unmet needs in oncology with a focus on orphan drug designations.

What Is the Investment Thesis for CTOR?

Citius Oncology, Inc. presents a focused investment opportunity within the oncology sector, primarily driven by the development of LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma. The orphan drug designation for LYMPHIR offers potential market exclusivity and accelerated regulatory pathways. Key value drivers include successful clinical trial outcomes and eventual FDA approval, which could significantly increase the company's market capitalization. However, the company's high beta of 3.43 indicates significant volatility, and the negative profit margin of -599.3% highlights financial risks. Growth catalysts include ongoing clinical trials and potential partnerships. Investors should carefully consider the risks associated with clinical-stage biopharmaceutical companies, including regulatory hurdles and competition from established players.

Based on FMP financials and quantitative analysis

CTOR Key Highlights

Market capitalization of $84.6M, reflecting its position as a smaller player in the biopharmaceutical industry.

• Gross margin of 80.0%, indicating strong potential profitability upon commercialization of its lead product.
• Profit margin of -599.3%, highlighting the current stage of development and investment in research and clinical trials.
• Beta of 3.43, suggesting higher volatility compared to the overall market.
• Focus on LYMPHIR, an orphan drug for relapsed or refractory cutaneous T-cell lymphoma, addressing an unmet medical need.

Who Are CTOR's Competitors?

CTOR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are CTOR's Key Strengths?

Focus on targeted oncology therapies.

• Orphan drug designation for LYMPHIR.
• Experienced management team.
• Strong gross margin potential.

What Are CTOR's Weaknesses?

Negative profit margin.

• High beta indicating volatility.
• Reliance on a single lead product candidate.
• Limited financial resources.

What Could Drive CTOR Stock Higher?

Announcement of clinical trial results for LYMPHIR.

• Potential FDA submission for LYMPHIR.
• Enrollment of patients in clinical trials.
• Advancing pipeline of oncology therapies.

What Are the Key Risks for CTOR?

Financial-distress signal — its Altman Z-Score of -2.05 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-99.5%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Clinical trial failures or delays.
• Regulatory hurdles and rejection of FDA submissions.
• Competition from other pharmaceutical companies.
• Financial risks associated with funding research and development.
• Market volatility and economic downturn.

What Are the Growth Opportunities for CTOR?

• LYMPHIR Clinical Development: The primary growth opportunity lies in the successful clinical development and eventual FDA approval of LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma. The market for CTCL therapeutics is estimated to grow, driven by the increasing prevalence of the disease and the need for more effective treatments. Positive clinical trial results and regulatory approval could lead to significant revenue generation and market share capture for Citius Oncology.
• Expansion into Additional Indications: Citius Oncology can explore expanding the use of LYMPHIR or other pipeline candidates into additional oncology indications. This would broaden the company's market reach and revenue potential. Identifying new therapeutic targets and conducting clinical trials to evaluate the efficacy of its therapies in these indications would be crucial for this growth strategy. The timeline for this expansion would depend on the success of ongoing and future clinical trials.
• Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with other pharmaceutical companies or research institutions can accelerate the development and commercialization of Citius Oncology's therapies. These partnerships can provide access to additional resources, expertise, and funding. Collaborations can also help to expand the company's pipeline and market reach. The timeline for establishing these partnerships will depend on the company's ability to identify and secure mutually beneficial agreements.
• Orphan Drug Designation Benefits: Leveraging the orphan drug designation for LYMPHIR provides several advantages, including market exclusivity and potential tax credits. The orphan drug designation incentivizes the development of therapies for rare diseases, which often face challenges in terms of market size and profitability. Citius Oncology can capitalize on these benefits to drive the development and commercialization of LYMPHIR. The ongoing benefits of the orphan drug designation will continue to support the company's growth.
• Geographic Expansion: Citius Oncology can explore expanding its market presence into new geographic regions. This would involve conducting clinical trials in different countries and obtaining regulatory approvals in those markets. Expanding into new markets can significantly increase the company's revenue potential and market share. The timeline for geographic expansion will depend on the company's ability to navigate the regulatory requirements and establish distribution networks in each target market.

What Are CTOR's Competitive Advantages?

• Orphan drug designation for LYMPHIR, providing market exclusivity.
• Proprietary technology and intellectual property related to its therapies.
• Strong relationships with key opinion leaders and clinical centers.
• Expertise in developing and commercializing oncology therapies.

What Does CTOR Do?

Citius Oncology, Inc. is a biopharmaceutical company dedicated to the development of innovative, targeted oncology therapies. As a subsidiary of Citius Pharmaceuticals, Inc., Citius Oncology focuses on addressing unmet medical needs in the treatment of cancer. The company's primary focus is the advancement of LYMPHIR, a promising therapeutic candidate designated as an orphan drug for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). LYMPHIR represents a significant opportunity to provide a novel treatment option for patients with this challenging condition. Headquartered in New York City, Citius Oncology leverages its strategic location to foster collaborations with leading research institutions and clinical centers. The company is committed to rigorous scientific research and clinical development to bring innovative therapies to market. Citius Oncology's business model centers around identifying and developing targeted therapies that have the potential to improve outcomes for cancer patients. The company is dedicated to advancing the field of oncology through innovation and a commitment to patient care. Citius Oncology's strategy involves a combination of internal research and development efforts, as well as potential partnerships and collaborations to expand its pipeline of oncology therapies. The company is focused on building a portfolio of targeted therapies that address a range of cancers and patient populations.

What Products and Services Does CTOR Offer?

• Develop novel targeted oncology therapies.
• Focus on unmet medical needs in cancer treatment.
• Advance LYMPHIR, an orphan drug for relapsed or refractory cutaneous T-cell lymphoma.
• Conduct rigorous scientific research and clinical development.
• Collaborate with leading research institutions and clinical centers.
• Identify and develop targeted therapies to improve outcomes for cancer patients.

How Does CTOR Make Money?

• Develop and commercialize targeted oncology therapies.
• Focus on orphan drug designations for rare cancers.
• Generate revenue through the sale of approved therapies.
• Potentially license or partner with other companies for development and commercialization.

What Industry Does CTOR Operate In?

Citius Oncology, Inc. operates within the drug manufacturing industry, specifically focusing on oncology. The oncology market is experiencing substantial growth, driven by an aging population and advancements in targeted therapies. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms. Citius Oncology's focus on orphan drugs provides a niche market opportunity, but also presents challenges related to clinical development and regulatory approval. The company's success will depend on its ability to navigate the complex regulatory environment and effectively commercialize its products.

Who Are CTOR's Key Customers?

• Adult patients with relapsed or refractory cutaneous T-cell lymphoma.
• Oncologists and other healthcare professionals who treat cancer patients.
• Hospitals and clinics that provide cancer treatment services.
• Potential partners and licensees in the pharmaceutical industry.

Company Profile

Citius Oncology, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Cranford, United States.

Citius Oncology, Inc. Financial Trajectory

Citius Oncology, Inc. (CTOR) reported $1.5M in revenue for Q3 FY2026, a decline of 10.4% compared to the prior quarter. The company recorded a net loss of $8.9M, with diluted EPS of $-0.08. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely.

How Citius Oncology, Inc. Is Valued

Citius Oncology, Inc. carries a market capitalization of $84.6M, placing it in the micro-cap category. Analyst price targets span from $6.00 to $6.00, with a consensus of $6.00. At the current price of $0.91, that implies approximately 559% upside potential. Relative to its peer group, CTOR's quantitative score of 17/100 is below the peer average of 51/100.

Return on equity for Citius Oncology, Inc. stands at -99.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -42.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -26.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.50 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -62.0%, the inverse of the P/E and a quick read on earnings relative to price.

Citius Oncology, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.05 places it in the distress zone, a signal of elevated financial risk.

Citius Oncology, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 334.9% below estimates on average.

The most recent 11 insider filings for Citius Oncology, Inc. break down as 0 sales and 11 purchases. On net that is roughly 6.1M shares acquired (about $0) — insiders putting money in tends to read as conviction.

CTOR Financials

CTOR Latest News

CTOR Analyst Consensus

CTOR MoonshotScore

Common Questions About CTOR (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources